Background : Regulatory T cells (Tregs) are known to be key regulators of immune responses in patients with autoimmune disease and infection and also for attenuating antitumor immunity by the host. It has been reported that high numbers of tumor-infiltrating Tregs might be associated with poor clinical outcomes for several malignant tumors. Therefore, this study aimed to examine the impact of tumor-infiltrating Tregs on the prognosis of gastric carcinoma patients. Methods : The immunohistochemical staining for anti-fork head Box P3 (FoxP3) antibody was performed by using a 3 mm core from the tumor specimens of each of the 173 gastric cancer patients for constructing a tissue microarray. FoxP3-positive Tregs were quantified by calculating the numbers of positive cells per 5 high-power fields on light microscopy. Thereafter, the 173 patients were subdivided into the low Tregs group (≤ 3/5 high power fields [HPF], n = 41) and the high Tregs group (> 3/5 HPF, n = 132). Results : The high Tregs group was significantly associated with a higher stage, more invasion depth and lymph node metastasis (p = 0.009, p = 0.036, p = 0.006, respectively). The high Tregs group showed significantly poorer overall survival and event-free survival (p = 0.004, p = 0.017, respectively) on the univariate analysis. The Tregs group and the tumor, node and metastasis stage were also independent prognostic factors that were significantly associated with overall survival (p = 0.025, p < 0.001, respectively) by multivariate analysis. Conclusions : Our results indicated that a high number of tumor-infiltrating FoxP3-positive Tregs could be an indicator of poor long term survival for gastric carcinoma patients.
Regulatory T cells (Tregs) are important T cells for preserving peripheral tolerance and they play a central role in several disease such as autoimmune disease, graft versus host disease and infectious diseases. The best defined Tregs CD4+ cells that constitutively express CD25. 1 For identifying CD4+CD25+ T cell, several markers such as CD45RB, CD38 and CD62L have been introduced in murine models. 2, 3 Fork head Box P3 (FoxP3) has recently been identified as a specific marker of CD4+CD25+ T cell.
FoxP3 is consistently expressed in naturally occurring CD4+CD-25+ Tregs populations and it is the master gene for development and differentiation of Tregs in the thymus and the periphery. 4 The tumor microenvironment is composed of tumor cells, immune cells and stromal cells, and this is an important factor in tumor growth, progression and regression. Tumor cells grow and propagate as a result of escaping attack of immune cells. Tregs show a high prevalence in malignant tumor patients and they attenuate antitumor immunity. 5 Especially, FoxP3-positive Tregs have been focused on because of their roles in the development and progression of tumors. Recent studies using FoxP3 as a marker of Tregs have also shown that tumor-infiltrating Tregs are associated with a worse prognosis for human malignant tumors such as breast, 6 lung, 7 ovary, 8 and liver tumors.
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Gastric carcinoma is one of the most common types of cancer. Although the incidence and mortality of gastric carcinoma have fallen, it remains the second most common cause of cancer deaths worldwide. 10 In Asian countries, including Korea, Japan, and China, gastric carcinoma causes major public health problems. However, the role of Tregs as a prognostic factor for gastric carcinoma is not understood. Therefore, we investigated the tumor-infiltrating FoxP3-positive Tregs in gastric carcinoma and their correlations with the clinicopathologic prognostic factors and gastric cancer patients' long-term survival.
MATERIALS AND METHODS

Patients and tissue samples
The patients who underwent radical gastrectomy for gastric carcinoma at Chonbuk National University Hospital between January 1997 and December 2005 were included in the present study. To minimize the confounding effects, a matching process was conducted. All of the patients who were in stage IV (n = 50) were included in this analysis. Thereafter, the patients who were in stage I, II or III were matched accoding to the following variables; gender, age (± 2 years), and the calendar year of the surgical operation (± 2 years). Among the 200 selected cases of gastric cancer, the paraffin-embedded tissue blocks of 27 cases were unavailable. Therefore, 173 cases of gastric cancer were finally included in the present study. All of these cases were reviewed and reclassified according to the World Health Organization classification criteria. 11 The pathologic staging was reviewed based on the tumor, node and metastasis (TNM) staging system of the American Joint Committee on Cancer. This study received the approval of the local ethics committee from Chonbuk National University Hospital's institutional review board. Informed consent was provided according to the Declaration of Helsinki. The patients were grouped according to their age, gender, the preoperative serum carcinoembryonic antigen level, the serum carbohydrate antigen (CA) 19-9 level, the serum CA72-4 level, the stage (I and II vs III and IV), the depth of tumor invasion, the presence of lymph node metastasis, the presence of distant metastasis, the histologic types and differentiation, and Lauren's classification
Immunohistochemical staining for the tissue microarray
The hematoxylin and eosin-stained sections from each paraffin-embedded, formalin-fixed block were utilized to define the diagnostic areas which were principally composed of tumor cells and stromal cells, and one 3.0 mm core was obtained from each case. These cores were inserted in a grid pattern into a recipient block by using a tissue arrayer. The 4 mm-sections were then cut from each tissue microarray and immunohistochemical staining for FoxP3 was performed by using the DAKO Envision system (DAKO, Carpinteria, CA, USA), which uses dextran polymers conjugated with horseradish peroxidase, to avoid any endogenous biotin contamination. Briefly, after deparaffinization, the tissue sections underwent a microwave antigen retrieval procedure in sodium citrate buffer (pH 9.0) for 10 minutes. After blocking the endogenous peroxidase, the sections were incubated with Protein Block Serum-Free (DAKO) at room temperature for 10 minutes to block the nonspecific staining, and then the sections were incubated for 12 hours at 4℃ with monoclonal antibodies against FoxP3 (1 : 50, clone 236A/E7, eBioscience, SanDiego, CA, USA). The peroxidase activity was detected with the enzyme substrate 3-amino-9-ethyl carbazole. For positive controls, normal tonsillar tissue sections were treated in the same manner. For negative controls, the sections were treated in the same manner except they were incubated with Tris-buffered saline without the primary antibody.
Quantitative assessment of the numbers of FoxP3-positive Tregs
For the quantification of the tumor infiltrating FoxP3-positive Tregs, the total numbers of FoxP3-positive cells in the intratumoral stroma of 5 high-power fields (HPF) were counted by two pathologists with consensus in all cases. Considering the limited area of the tumor component in some cases, and especially in the cases of early gastric carcinoma, the 5 HPFs were thoroughly examined.
The counting of FoxP3-positive Tregs was conducted without the pathologists having any clinical information about the cases. Slide examinations were performed using a Nikon ECLIPSE 80i light microscope (Nikon, Tokyo, Japan) with 40× objective lens (Plan Fluor 40×/ 0.75, Nikon). The field area of one HPF was 0.307 mm 2 . Therefore, the total area that was analyzed per case was 1.535 mm 2 .
Statistical analysis
The cut-off number of FoxP3-positive Tregs was assessed by the area under the curve (AUC) of the receiver operating characteristic (ROC) curve for overall survival, and this was determined by the highest positive likelihood ratio (sensitivity/[1-specificity]). The cut-off number for the ideal test is presented as the AUC 1.000 with sensitivity of 1 and specificity of 1. If the area under the ROC curve of a test is greater than 0.5, then the cut-off number has a positive value and it can be calculated. Then, using this cut-off of number of Tregs, the patients were separated into the low and high Tregs subgroups for further analysis. The comparisons between the numbers of tumor-infiltrating FoxP3-positive Tregs and the clinical factors were tested by t-tests and chi-square tests. The end points of interest were overall survival (OS) and event-free survival (EFS). The end point of follow-up was the date of the last contact or the date of death through November 2007. The patients who were alive at last contact were treated as censored for OS analysis. The EFS was calculated from the time of diagnosis to the date of recurrence, death or the last contact. The patients who were alive at the last contact and who had not recurred were treated as censored data for the EFS analysis. Univariate and multivariate Cox proportional hazards regression analyses were performed to estimate the impact of the numbers of tumor infiltrating FoxP3-positive Treg and the clinicopathologic factors on OS and EFS. The Kaplan-Meier survival curves were constructed to further illustrate the impact on OS and EFS, when indicated. p-values less than 
RESULTS
The association of tumor infiltrating FoxP3-positive Tregs with the clinicopathologic characteristics of the gastric carcinoma patients
The expression of FoxP3-positive Tregs in the gastric cancer tissues, as revealed by immunohistochemical staining, is shown in Fig. 1 . The average number of tumor-infiltrating FoxP3-positive Tregs per 5 HPFs was 15.91 (range, 0 to 181).
In this study, the cut-off number of Tregs was determined by using the AUC of the ROC curve that yielded the maximal sensitivity plus specificity for overall survival. The AUC was 0.525, and the cut-off level was determined to be 3 Tregs per 5 HPFs. According to the cut-off number of Tregs, the 173 gastric cancer patients were classified into two groups; the low Tregs group (≤ 3/5 HPF, n = 41), and the high Tregs group (> 3/5 HPF, n = 132).
For the 173 gastric cancer patients, there were significant correlations between the high Tregs group and a higher TNM stage (p = 0.009), a greater invasion depth (p = 0.036), and the presence of lymph node metastasis (p = 0.006). There was no significant correlation between the Tregs groups and the tumor differentiation, Lauren's classification, the tumor growth pattern, the presence of distant metastasis and the pre-operative serum tumor markers. The clinicopathologic features of the gastric carcinoma patients and their relations between the Tregs group are shown in Table 1 . Variables considered in the analysis were the preoperative serum level of CEA and CA19-9, TNM stage and Tregs group. OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; Tregs, regulatory T cells; TNM, tumor, node and metastasis. Table 2 . Clinicopathologic factors and their effect on event-free survival and overall survival by univariate Cox proportional hazards regression analysis
The prognostic significance of infiltrating FoxP3-positive Tregs in the gastric carcinoma patients
The mean follow-up duration of the 173 gastric cancer patients was 36.79 months (range, 1 to 120 months). The patients in the high Tregs group also had significantly poorer OS (p = 0.004) and EFS (p = 0.017) than the patients in the low Tregs group, according to the univariate analysis (Table 2) . By multivariate analysis, the Tregs group (p = 0.025) and the TNM stage (p < 0.001) were independent predictors of OS (Table 3) . However, on the multivariate analysis for EFS, the TNM stage was the only significant independent prognostic marker. The OS and EFS according to the Tregs groups are plotted in Fig. 2 .
DISCUSSION
This study demonstrated that having more than 3 tumor-infiltrating FoxP3-positive Tregs per 5 HPFs (1.535 mm 2 ) was significantly associated with advanced cancer characteristics, such as advanced tumor invasion, lymph node metastasis and a high TNM stage. Moreover, the patients in the high Tregs group showed a significant shorter OS and EFS as compared with that of the low Tregs group patients. These results indicate that Tregs may play an important role in tumor progression and they may be a clinically significant prognostic indicator of gastric carcinoma. The cut-off number of 3 Tregs per 5 HPFs that we found is comparable with that (6 Tregs per 10 HPFs) reported by Perrone et al. 12 In agreement with our findings, Perrone et al. 12 have shown that a high number of intratumoral FoxP3-positive Tregs were associated with an adverse prognosis in 110 gastric cancer patients. Although FoxP3 was not used as a marker of Tregs, there are some reports that Tregs are associated with progression of gastric carcinoma. 13, 14 Increased numbers of CD4+CD25+ Tregs in the peripheral blood of gastric cancer patients were associated with a high tumor stage and poor survival, 13 and the populations of CD4+CD25+ T cells in the tumor-infiltrating lymphocytes of gastric cancer patients with advanced disease were significantly higher than that of the tumor-infiltrating lymphocytes in the patients with early stage disease.
14 Furthermore, increasing evidences has indicated that tumor-infiltrating Tregs play a major role in tumor progression and they have an influence on patients' survival; the importance of Tregs in tumor immunology has been emphasized in various human malignant tumors in addition to gastric carcinoma. The number of Tregs is a predictor of recurrence in patients with stage I non-small cell lung cancer.
7 FoxP3-positive Tregs have been reported to be a novel marker for identifying late-relapse patients with breast cancer. 6 Sasada et al. 15 have reported that patients with recurrent gastric carcinoma show a significantly higher relative prevalence of the CD25+ T cell subset in the peripheral blood than that of patients with primary gastric carcinoma. On the other hand, some conflicting results also have been reported. According to the report of Mizukami et al., 16 the number of tumor-infiltrating Tregs was not associated with the survival of gastric carcinoma patients. In terms of the localization patterns of Tregs, Overall survival probability 17 A subset of dendritic cells that was exposed to tumor cells acquired the capacity to secrete TGF-b and to promote the proliferation of naturally occurring Tregs in vivo. 18 It has been suggested that Tregs' suppressive functions occurs by four basic pathways: inhibitory cytokines, cytolysis, metabolic disruption, and modulation of dendritic cell maturation or fuction.
19 Tregs suppress the proliferation and differentiation of the naive T cells and they also suppress the activity of differentiated CD4+ and CD8+ T cells, natural killer cells and dendritic cells. 20 In addition, Tregs suppress B cells by inhibiting antibody production and proliferation. 21 For the results of the present study, tumorinfiltrating Tregs were associated with a high stage and advanced invasiveness of gastric carcinoma. Therefore, our study also supports the suggestion that Tregs might be involved in the suppression of anti-tumor immunity.
In this study, tumor-infiltrating FoxP3-positive Tregs were associated with lymph node metastasis. In addition, all of the four cases with distant metastasis were included in the high Tregs group and no cases of the low Tregs group showed distant metastasis. In the tumor microenvironment, the tumor cells and the induced Tregs release excessive TGF-b. The released TGF-b induces the expression of VEGF 22 and the cancer cells also produce VEGF. 17 In addition, the overexpression of VEGF by the tumor increases the presence of regulatory T cells. 23 VEGF participates in not only angiogenesis, but also lymphangiogenesis, 24 and a previous study has shown positive relationships between the Fox-P3 expression, TGF-b, VEGF and angiogenesis. 25 It also has been reported that the number of Tregs are increased in the draining lymph nodes of gastric cancer patients. 26 Moreover, in human metastatic melanoma lymph nodes, FoxP3 expressing CD4+CD-25+ T cells are overexpressed and they inhibit the CD4+CD25-T cells as well as the CD8+ T cells. 27 These findings suggested that the recruited Tregs not only inhibit the immune response to tumor antigens, but they may also induce angio-and lymphangiogenesis at the primary and metastatic sites, and then they promote tumor growth and spread into distant sites such as lymph nodes or other organs.
The therapeutic strategies for cancer by inducing the depletion of Tregs have been evaluated in several animal models and clinical trials. Administration of anti-CD25 monoclonal antibody facilitated anti-tumor immunity and it induced tumor regression in vivo. 28 Denileukin diftitox, which is a recombinant IL-2 diphteria toxin conjugate, selectively eliminates CD25-expressing Tregs from the peripheral blood of cancer patients.
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The administration of low dose cyclophosphamide induces decreased numbers of Tregs and it inhibits the suppressive capability of Tregs. 30 Considering these findings that high numbers of Tregs are associated with advanced cancer characteristics and a poor prognosis, the use of new therapeutic strategies for modulating Tregs may be helpful for improving the prognosis of gastric carcinoma patients.
In conclusion, we showed that tumor-infiltrating FoxP3-positive Tregs were associated with the tumor stage, the depth of tumor invasion, lymph node metastasis and patient survival, and these findings support that Tregs may play a key role in the tumor progression of patients with gastric carcinoma. Furthermore, these findings may be helpful for establishing novel immunotherapy for gastric carcinoma.
